Switzerland· 68526002
Ezetimib Rosuvastatin Zentiva
A rosuvastatin and ezetimibe product containing ezetimibum, rosuvastatinum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rosuvastatin and ezetimibe is registered in 9 of 19 countries.
Countries holding a registration under ATC C10BA06 (rosuvastatin and ezetimibe), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 7 of them publish a price we can compare per daily dose
Rosuvastatin and ezetimibe · ATC C10BA06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- ezetimibum, rosuvastatinum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- C10BA06
- ATC class
- Rosuvastatin and ezetimibe
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680685260024Blist 90 StkCHF 77.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under C10BA06
Rosuvastatin and ezetimibe, as other registers publish it.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- ItalyAUROZEBAURORA BIOFARMA S.R.L.
- NetherlandsAyadont 10 mg/10 mg, harde capsulesEgis Pharmaceuticals Plc
- NetherlandsAyadont 20 mg/10 mg, harde capsulesEgis Pharmaceuticals Plc
- NetherlandsAyadont 40 mg/10 mg harde capsuleEgis Pharmaceuticals Plc
- NetherlandsAyadont 5 mg/10 mg, harde capsulesEgis Pharmaceuticals Plc
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd061b13-ab14-478a-be3d-04d9a35be721 GET /v1/drugs/fd061b13-ab14-478a-be3d-04d9a35be721?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ezetimibum 10 mg + rosuvastatinum 10 mg",
"valid_from": "2023-06-01",
"limitations": "[{\"description\":\"EZETIMIB ROSUVASTATIN ZENTIVA wird als Ersatztherapie bei erwachsenen Patienten vergütet, die bereits Ezetimib und Rosuvastatin als separate Tabletten in der gleichen Dosierungsstärke erhalten und die Kriterien entsprechend der Limitierungen der Ezetimib- und Rosuvastatin-Monopräparate erfüllen.<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-06-01\",\"validTo\":null}]",
"galenic_form": "Filmtabl 10 mg/10 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2023-06-01",
"self_retention_pct": 10
}See everything about rosuvastatin and ezetimibe.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.